In the SUNBEAM and RADIANCE studies, participants received oral ozanimod hydrochloride 1 or 0.5 mg/day or intramuscular IFN beta-1a 30 µg a week for ≥12 months (SUNBEAM; n=1,346) or 24 months (RADIANCE; n=1,313). The effects on the whole BVL were presented by Prof. Giancarlo Comi (Vita-Salute San Raffaele University, Italy) [1]. After 12 months in SUNBEAM, whole BVL was -0.61, -0.49, and -0.41 in the IFN-beta-1a, ozanimod 0.5 mg, and ozanimod 1 mg group, respectively (nominal P-values for ozanimod 0.5 mg and 1 mg: P=0.0092 and P<0.0001, respectively). After 24 months in RADIANCE, whole BVL was -0.94, -0.71, and -0.71 in the 3 respective groups (nominal P-values for ozanimod 0.5 mg and 1 mg: P=0.0002 and P<0.0001, respectively). Both ozanimod doses also reduced two prespecified exploratory endpoints vs IFN: cortical grey matter volume loss and thalamic volume loss.
In a single-centre study, the long-term efficacy of IFN (n=562) and azathioprine (n=373) in relapsing-remitting MS was retrospectively compared [2]. At 10 year follow-up, 50% of patients were free of any disability worsening and 25% were relapse-free, with no differences between IFN and azathioprine. Safety was also similar, but higher adherence in the azathioprine group suggests better tolerability of azathioprine.
In another study, longitudinal changes of resting state functional connectivity were evaluated in 50 relapsing-remitting MS patients treated with fingolimod (n=23) or natalizumab (n=27) over a period of 2 years [3]. Significant reduction of disease activity, stability of the EDSS score, and improvement of cognitive performance were found in both groups. Resting state functional connectivity significantly increased in the main large-scale functional networks in fingolimod- and natalizumab-treated groups, possibly reflecting a recovery from disease activity before treatment start and subsequent disease stability.
Two anti-CD20 monoclonal antibodies, one chimeric (rituximab; n=53) and one humanised (ocrelizumab; n=38) were compared [4]. B cell levels in the peripheral blood were equally decreased. However, CD4+ and CD8+ lymphocyte reduction was more pronounced in the ocrelizumab group. Patients treated with ocrelizumab presented with 10.6% more reduced overall lymphocyte count (P=0.030) and 8% more increased of CD4/CD8 ratio (P=0.042) after 1 month. After 3 months, patients treated with ocrelizumab presented with 15.2% more reduction of CD4+ lymphocytes (p=0.034).
- Arnold D, et al. EAN 2019, O1201.
- Mecchi C, et al. EAN 2019, O4110.
- Rocca MA, et al. EAN 2019, O4112.
- Nozzolillo A, et al. EAN 2019, EPO2227.
Posted on
Previous Article
« Fremanezumab results of the FOCUS study Next Article
Opicapone: follow-up on the BIPARK I and II trials »
« Fremanezumab results of the FOCUS study Next Article
Opicapone: follow-up on the BIPARK I and II trials »
Table of Contents: EAN 2019
Featured articles
Letter from the Editor
Alzheimer’s Disease and other Dementias
A necessary shift of focus to the earlier stages of Alzheimer’s
Antipsychotics increase mortality regardless of comorbidity
Epilepsy
Neuroinflammatory pathways as biomarkers and treatment targets
Long-term effect of recurrent febrile seizures
Migraine
The role of neurogenic inflammation in migraine
Multiple Sclerosis
Treating MS from disease onset
Randomised and observational studies comparing treatments
Autologous haematopoietic stem cell transplantation
Neuromuscular Disorders
Parkinson's Disease and other Movement Disorders
Inflammation may change the course of Parkinson’s disease
Opicapone: follow-up on the BIPARK I and II trials
Epigallocatechin gallate does not modify MSA progression
Stroke
Thrombo-inflammation during ischaemia/reperfusion
Related Articles
June 16, 2021
Stroke uncommon in critically ill COVID-19 patients
January 11, 2022
Drug-eluting stents reduce in-stent restenosis, stroke
November 11, 2021
CTA identifies stroke patients most likely to benefit from thrombectomy
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com